103 related articles for article (PubMed ID: 27490860)
21. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
[TBL] [Abstract][Full Text] [Related]
22. Determination of key receptor-ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology model.
Sukalovic V; Soskic V; Sencanski M; Andric D; Kostic-Rajacic S
J Mol Model; 2013 Apr; 19(4):1751-62. PubMed ID: 23300056
[TBL] [Abstract][Full Text] [Related]
23. Exploration of N-arylpiperazine Binding Sites of D2 Dopaminergic Receptor.
Soskic V; Sukalovic V; Kostic-Rajacic S
Mini Rev Med Chem; 2015; 15(12):988-1001. PubMed ID: 25723457
[TBL] [Abstract][Full Text] [Related]
24. Homology modeling of the dopamine D2 receptor and its testing by docking of agonists and tricyclic antagonists.
Teeter MM; Froimowitz M; Stec B; DuRand CJ
J Med Chem; 1994 Sep; 37(18):2874-88. PubMed ID: 7915325
[TBL] [Abstract][Full Text] [Related]
25. Proof of concept study for designed multiple ligands targeting the dopamine D2, serotonin 5-HT2A, and muscarinic M1 acetylcholine receptors.
Szabo M; Lim HD; Herenbrink CK; Christopoulos A; Lane JR; Capuano B
J Med Chem; 2015 Feb; 58(3):1550-5. PubMed ID: 25590655
[TBL] [Abstract][Full Text] [Related]
26. Main interactions of dopamine and risperidone with the dopamine D2 receptor.
Martínez A; García-Gutiérrez P; Zubillaga RA; Garza J; Vargas R
Phys Chem Chem Phys; 2021 Jul; 23(26):14224-14230. PubMed ID: 34159983
[TBL] [Abstract][Full Text] [Related]
27. Predictions of binding for dopamine D2 receptor antagonists by the SIE method.
Wang YT; Su ZY; Hsieh CH; Chen CL
J Chem Inf Model; 2009 Oct; 49(10):2369-75. PubMed ID: 19769359
[TBL] [Abstract][Full Text] [Related]
28. The action of a negative allosteric modulator at the dopamine D
Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the conformational space of the active site of D
Tosso RD; Zarycz MNC; Schiel A; Goicoechea Moro L; Baldoni HA; Angelina E; Enriz RD
J Comput Chem; 2022 Jul; 43(19):1298-1312. PubMed ID: 35638694
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the Glutamate Agonist LY404,039 Binding to Nonstatic Dopamine Receptor D2 Dimer Structures and Consensus Docking.
Salmas RE; Seeman P; Aksoydan B; Erol I; Kantarcioglu I; Stein M; Yurtsever M; Durdagi S
ACS Chem Neurosci; 2017 Jun; 8(6):1404-1415. PubMed ID: 28272861
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and characterization of selective dopamine D2 receptor antagonists.
Vangveravong S; McElveen E; Taylor M; Xu J; Tu Z; Luedtke RR; Mach RH
Bioorg Med Chem; 2006 Feb; 14(3):815-25. PubMed ID: 16288878
[TBL] [Abstract][Full Text] [Related]
32. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.
Boeckler F; Lanig H; Gmeiner P
J Med Chem; 2005 Feb; 48(3):694-709. PubMed ID: 15689154
[TBL] [Abstract][Full Text] [Related]
33. Investigating the structural impact of S311C mutation in DRD2 receptor by molecular dynamics & docking studies.
Podder A; Pandey D; Latha N
Biochimie; 2016 Apr; 123():52-64. PubMed ID: 26805384
[TBL] [Abstract][Full Text] [Related]
34. Binding Interactions of Dopamine and Apomorphine in D2High and D2Low States of Human Dopamine D2 Receptor Using Computational and Experimental Techniques.
Durdagi S; Salmas RE; Stein M; Yurtsever M; Seeman P
ACS Chem Neurosci; 2016 Feb; 7(2):185-95. PubMed ID: 26645629
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.
Madapa S; Gadhiya S; Kurtzman T; Alberts IL; Ramsey S; Reith M; Harding WW
Eur J Med Chem; 2017 Jan; 125():255-268. PubMed ID: 27688181
[TBL] [Abstract][Full Text] [Related]
36. Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.
Kopinathan A; Scammells PJ; Lane JR; Capuano B
Future Med Chem; 2016 Jul; 8(11):1349-72. PubMed ID: 27357619
[TBL] [Abstract][Full Text] [Related]
37. Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors.
Duan X; Zhang M; Zhang X; Wang F; Lei M
J Mol Graph Model; 2015 Apr; 57():143-55. PubMed ID: 25728902
[TBL] [Abstract][Full Text] [Related]
38. Analysis of binding residues between scorpion neurotoxins and D2 dopamine receptor: a computational docking study.
Sudandiradoss C; George Priya Doss C; Rajasekaran R; Purohit R; Ramanathan K; Sethumadhavan R
Comput Biol Med; 2008 Oct; 38(10):1056-67. PubMed ID: 18799158
[TBL] [Abstract][Full Text] [Related]
39. Dopamine displays an identical apparent affinity towards functional dopamine D1 and D2 receptors in rat striatal slices: possible implications for the regulatory role of D2 receptors.
Schoffelmeer AN; Hogenboom F; Mulder AH; Ronken E; Stoof JC; Drukarch B
Synapse; 1994 Jul; 17(3):190-5. PubMed ID: 7974202
[TBL] [Abstract][Full Text] [Related]
40. Theoretical study of 3-D molecular similarity and ligand binding modes of orthologous human and rat D2 dopamine receptors.
Soriano-Ursúa MA; Ocampo-López JO; Ocampo-Mendoza K; Trujillo-Ferrara JG; Correa-Basurto J
Comput Biol Med; 2011 Jul; 41(7):537-45. PubMed ID: 21621758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
